[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Haiyan Pan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100603677","screening-of-predictive-biomarkers-for-cardiorenal-syndrome-100603677",false,"NCT07139626","Screening of Predictive Biomarkers for Cardiorenal Syndrome","Screening and Validation of Serum Biomarkers (SLPI, Serpin E1, CXCL10, CXCL13, Properdin) for Predicting Cardiorenal Syndrome in Patients With Chronic Heart Failure: A Prospective Cohort Study","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Diagnosed with stable chronic heart failure (HF) according to the 2024 Chinese Heart Failure Diagnosis and Treatment Guideline.\n* HF subtypes include:\n\nHFrEF (LVEF ≤40%), HFmrEF (LVEF 41 - 49%), HFpEF (LVEF ≥50%).\n\n* Willing to provide blood samples for biomarker analysis.\n* Able to comply with follow - up visits and study procedures for 12 months.\n* Note: For the screening phase, 10 patients will be included for each subtype; for the validation phase, 30 patients will be included for each subtype.\n\nExclusion Criteria:\n\n* History of long-term dialysis or kidney surgery.\n* Acute kidney injury (AKI) within the past 3 months.\n* Use of nephrotoxic drugs within the past 3 months.\n* Diagnosis of autoimmune diseases (e.g., lupus, rheumatoid arthritis).\n* Active malignancy or history of cancer treatment within the past 5 years.\n* Acute infectious diseases at the time of enrollment.\n* Severe liver dysfunction (e.g., cirrhosis, ALT\u002FAST \\>3× upper limit of normal).\n* Pregnancy or lactation.\n* Inability or unwillingness to provide informed consent.\n* Participation in another interventional clinical trial within the past 30 days.","ALL","18 Years","75 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","This study aims to explore the predictive value of specific biomarkers for cardiorenal syndrome (CRS) in patients with chronic heart failure (CHF).\n\nBuilding on previous research using Luminex technology, which identified that serum levels of SLPI, serpin E1, CXCL10, and CXCL13 were significantly higher, while properdin levels were lower in patients with post-cardiac surgery acute kidney injury (AKI) compared to those without renal impairment, this study will further investigate these biomarkers in the context of CRS.\n\nAdults aged 18-75 with stable CHF (including HFrEF, HFmrEF, and HFpEF subtypes) will be conducted in two phases:1. Screening phase: Compare serum levels of the above biomarkers between 30 CHF patients without kidney dysfunction and 30 CHF patients with CRS to identify biomarkers with significant differences. 2. Validation phase: Follow 90 CHF patients with normal kidney function for 1 year, and divide them into CHF-only and CRS groups based on renal function (creatinine and eGFR) after 1 year. The study will verify the predictive value of the screened biomarkers by comparing their levels before and after follow-up, analyzing correlations with NT-proBNP, creatinine, and eGFR, and using receiver operating characteristic (ROC) curves and area under the curve (AUC) to evaluate their predictive efficacy for CRS. The optimal predictive biomarker for this syndrome will be determined.\n\nThe participants will:\n\nProvide blood samples for the detection of biomarkers and liver and kidney function indicators.\n\nReceive one year of standardized heart failure treatment. Undergo regular follow-up visits.",[25],"Cardiorenal Syndrome (CRS)","RECRUITING","2026-02-24",{"date":29,"type":30},"2026-02-27","ACTUAL",{"date":32,"type":30},"2025-09-15",{"date":34,"type":21},"2027-12-31",{"name":36,"class":37},"Haiyan Pan","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":57,"locationsCount":38},"100605811","exercise-rehabilitation-for-cardiorenal-syndrome-in-hfref-patients-100605811","NCT07167368","Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients","Efficacy and Safety of Home-Based Exercise Rehabilitation in Patients With Cardiorenal Syndrome Complicated by Chronic Heart Failure With Reduced Ejection Fraction (HFrEF): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with chronically stable HFrEF complicated by kidney dysfunction (eGFR \\\u003C 90 mL\u002Fmin\u002F1.73m²)\n* NYHA class II-III\n* Low risk in exercise risk assessment\n* Aged 18-75 years\n\nExclusion Criteria:\n\n* Uncontrolled hypertension\n* Severe arrhythmias (including frequent ventricular premature contractions, ventricular tachycardia, rapid atrial fibrillation, sick sinus syndrome, and second-degree or higher atrioventricular block)\n* Obstructive hypertrophic cardiomyopathy\n* Moderate to severe stenotic valvular heart disease\n* Deep vein thrombosis or pulmonary embolism\n* History of syncope\n* Severe anemia\n* Abnormal thyroid function\n* Severe pulmonary diseases\n* Mental illnesses\n* Osteoarticular or muscular diseases that impede rehabilitation training",{"count":47,"type":21},60,"INTERVENTIONAL",[50],"NA","This study aims to investigate the efficacy and safety of exercise rehabilitation in patients with cardiorenal syndrome (CRS).\n\nBuilding on previous research demonstrating that exercise rehabilitation can effectively improve cardiac function and cardiopulmonary endurance in patients with chronic heart failure, this study will further explore its role in the context of CRS, a condition where such effects remain understudied. CRS patients typically exhibit reduced cardiopulmonary endurance, with significantly lower peak oxygen uptake (VO₂ peak) and 6-minute walk test (6MWT) distance compared to non-CRS patients.\n\nAdults aged 18-75 with chronic heart failure with reduced ejection fraction (HFrEF) complicated by chronic renal insufficiency will be enrolled and randomly assigned to two groups: 1. Basic treatment group: 30 patients receive only basic drug treatment for 6 months. 2. Exercise rehabilitation group: 30 patients receive basic drug treatment combined with home-based exercise rehabilitation for 6 months (with personalized exercise prescriptions formulated based on cardiopulmonary exercise test results or 6MWT for those unable to complete the former). The study will explore the efficacy and safety of exercise rehabilitation in the prevention and management of CRS by comparing changes in target biomarkers, renal function indicators, cardiac function indicators, cardiopulmonary exercise test results, Minnesota Living with Heart Failure Questionnaire scores, and the incidence of adverse events before and after treatment between the two groups.\n\nThe participants will:\n\nComplete cardiopulmonary exercise tests or 6MWT before treatment initiation. Receive basic drug treatment; those in the exercise rehabilitation group will additionally perform home-based exercise rehabilitation according to the exercise prescription.\n\nAttend regular follow-up visits within 6 months. Undergo assessments of related indicators (biomarkers, renal function, cardiac function, etc.) before and after treatment.",[53],"Cardiorenal Syndrome",{"date":29,"type":30},{"date":32,"type":30},{"date":34,"type":21},{"name":36,"class":37},""]